Italia markets close in 14 minutes

Ipsen S.A. (0MH6.IL)

IOB - IOB Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
114,00-2,70 (-2,31%)
In data: 03:37PM BST. Mercato aperto.

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Settore/iHealthcare
SettoreDrug Manufacturers - Specialty & Generic
Impiegati a tempo pieno5.300

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. David LoewMD, CEO & Director2,22MN/D1967
Mr. Aymeric Le ChatelierExec. VP & Group CFON/DN/D1969
Dr. Aidan Murphy Ph.D.Exec. VP of Technical OperationsN/DN/D1966
Mr. Craig MarksVice-Pres of Investor RelationsN/DN/DN/D
Mr. Francois GarnierExec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics OfficerN/DN/D1962
Ms. Gwenan WhiteExec. VP of Communications, Public Affairs & SustainabilityN/DN/DN/D
Mr. Regis MulotExec. VP & Chief HR OfficerN/DN/D1966
Ms. Dominique BeryHead of Nordics & BalticsN/DN/D1971
Dr. Yan Moore M.D.Sr. VP & Head of Oncology Therapeutic AreaN/DN/D1967
Dr. Alexander McEwanVice-Pres & Head of RadiopharmaceuticalsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Governance aziendale

L'ISS Governance QualityScore di Ipsen S.A. al 1 ottobre 2023 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.